Review

Central Sensitization in Chronic Pain Conditions: Mechanisms, Clinical Implications, and Treatment Strategies

SUSHIL KUMAR SV *

Posted Date: 20 March 2025

doi: 10.20944/preprints202503.1506.v1

Keywords: Central sensitization; chronic pain; fibromyalgia; neuropathic pain; neuroplasticity; pain modulation; treatment strategies; hyperalgesia; neuromodulation; pain mechanisms

Review

Central Sensitization in Chronic Pain Conditions: Mechanisms, Clinical Implications, and Treatment Strategies

Sushil Kumar SV

Kannur Medical College, Anjarakandy, Kannur, Kerala, India; drssompur@hotmail.com

Abstract: Central sensitization is a key mechanism underlying chronic pain syndromes, including fibromyalgia, neuropathic pain, and migraine. This review aims to explore the physiological and pathological aspects of central sensitization, elucidate its role in chronic pain conditions, and assess current and emerging treatment strategies to manage its effects. A comprehensive literature review was conducted by analyzing recent clinical and preclinical studies on central sensitization. Databases such as PubMed, Scopus, and Google Scholar were searched for relevant articles focusing on neurophysiological mechanisms, diagnostic criteria, and treatment interventions. Studies on pharmacological, non-pharmacological, and neuromodulatory approaches were included to provide a holistic view of the clinical implications. Central sensitization is primarily driven by maladaptive neuroplasticity, including increased excitability of nociceptive neurons, impaired inhibitory control, and glial activation. It contributes to heightened pain perception, spontaneous pain, and widespread hyperalgesia in conditions like fibromyalgia and neuropathic pain. Current treatment approaches include pharmacological agents such as NMDA receptor antagonists, gabapentinoids, and antidepressants, alongside non-pharmacological interventions like cognitive-behavioral therapy, exercise, and neuromodulation techniques. Despite these advancements, treatment responses vary, highlighting the need for personalized, multimodal therapeutic strategies. Understanding central sensitization is crucial for improving chronic pain management. Although various treatments show promise, there is no universal solution due to individual variability in pain processing. Future research should focus on identifying biomarkers for central sensitization, optimizing combination therapies, and exploring novel neuroplasticity-modulating interventions. A multidisciplinary approach integrating pharmacological, psychological, and rehabilitative strategies is essential for effective pain management.

Keywords: central sensitization; chronic pain; fibromyalgia; neuropathic pain; neuroplasticity; pain modulation; treatment strategies; hyperalgesia; neuromodulation; pain mechanisms

1. Introduction

Chronic pain affects approximately 20% of the global population, posing significant challenges to healthcare systems worldwide and severely impacting patients' quality of life [1,2]. Traditional approaches to pain management have often focused on peripheral mechanisms and nociceptive pathways. However, mounting evidence suggests that central nervous system alterations play a crucial role in the persistence and amplification of pain signals, particularly in conditions where pain extends beyond the expected healing time or occurs in the absence of clear tissue damage [3].

Central sensitization (CS) represents a key neurophysiological phenomenon characterized by increased responsiveness of nociceptive neurons in the central nervous system to normal or subthreshold afferent input [4]. This heightened state of sensory processing contributes to the development and maintenance of various chronic pain conditions, including fibromyalgia, complex regional pain syndrome (CRPS), irritable bowel syndrome (IBS), temporomandibular disorders (TMD), and certain types of headache disorders [5,6].

 doi:10.20944/preprints202503.1506.v1

Understanding the intricate mechanisms of central sensitization provides critical insights into the pathophysiology of these conditions and offers potential targets for therapeutic intervention. Despite significant advancements in our understanding of central sensitization over the past two decades, translating this knowledge into effective clinical interventions remains challenging due to the complex and heterogeneous nature of chronic pain conditions [7].

This review aims to comprehensively examine the neurophysiological underpinnings of central sensitization, its clinical manifestations across various pain conditions, current diagnostic approaches, and treatment strategies targeting central mechanisms. Additionally, we explore emerging therapeutic modalities and future directions in research that may enhance our ability to manage chronic pain conditions characterized by central sensitization.

2. Methodology

2.1. Search Strategy and Study Selection

A comprehensive literature review was conducted to identify relevant studies on central sensitization in chronic pain conditions. The search was performed across multiple electronic databases, including PubMed/MEDLINE, Scopus, Embase, Web of Science, and Google Scholar. The search strategy employed various combinations of the following keywords and Medical Subject Headings (MeSH) terms: "central sensitization," "central sensitivity syndrome," "chronic pain," "fibromyalgia," "neuropathic pain," "hyperalgesia," "allodynia," "pain modulation," "neuroplasticity," "treatment," "management," "pharmacotherapy," "non-pharmacological interventions," and "neuromodulation."

The initial search yielded 4,287 articles, which were further filtered based on the following inclusion criteria:

- Original research articles, systematic reviews, meta-analyses, and clinical trials published in peer-reviewed journals
- Studies published in English between January 2000 and October 2024
- Studies focusing on the neurophysiological mechanisms of central sensitization
- Clinical studies evaluating diagnostic criteria or assessment tools for central sensitization
- Intervention studies examining pharmacological, non-pharmacological, or neuromodulatory approaches for managing conditions associated with central sensitization

Exclusion criteria included:

- Case reports and case series with fewer than 10 participants
- Studies focusing exclusively on acute pain without relevance to central sensitization
- Animal studies without clear translational implications for human conditions
- Conference abstracts and unpublished dissertations
- Duplicate publications or secondary analyses of previously reported data

2.2. Data Extraction and Analysis

After applying the inclusion and exclusion criteria, 782 articles were selected for full-text review. Two independent reviewers assessed the methodological quality and relevance of each study using standardized quality assessment tools appropriate for each study design, including the Cochrane Risk of Bias Tool for randomized controlled trials and the Newcastle-Ottawa Scale for observational studies.

Data extraction was performed using a standardized form that captured information on study design, sample characteristics, methodological approaches, outcome measures, key findings, and limitations. Discrepancies in data extraction or quality assessment were resolved through discussion with a third reviewer until consensus was reached.

The extracted data were synthesized narratively, organized according to the following thematic areas:

 doi:10.20944/preprints202503.1506.v1

1. Neurophysiological mechanisms underlying central sensitization
2. Clinical manifestations and diagnostic approaches
3. Pharmacological interventions
4. Non-pharmacological interventions
5. Neuromodulatory approaches
6. Emerging therapies and future directions

Given the heterogeneity of study designs, populations, and outcome measures, a formal meta-analysis was not conducted. Instead, we adopted a narrative synthesis approach to integrate findings across studies and identify consistent patterns, contradictions, and knowledge gaps in the literature.

3. Neurophysiological Mechanisms of Central Sensitization

3.1. Definition and Basic Concepts

Central sensitization refers to an amplification of neural signaling within the central nervous system that elicits pain hypersensitivity [3]. Unlike nociceptive pain, which serves as a protective mechanism triggered by actual or potential tissue damage, central sensitization represents a pathological state in which pain perception is dissociated from ongoing peripheral input [4].

The phenomenon was first described by Woolf and colleagues in 1983, who demonstrated that brief noxious inputs could trigger prolonged changes in spinal cord neuronal excitability, leading to enhanced responses to subsequent stimuli [119]. Since this seminal work, our understanding of central sensitization has evolved substantially, encompassing a complex array of neurobiological mechanisms that occur at multiple levels of the neuraxis.

Central sensitization manifests clinically as:

- Hyperalgesia (increased pain from stimuli that normally provoke pain)
- Allodynia (pain due to a stimulus that does not normally provoke pain)
- Secondary hyperalgesia (increased sensitivity in undamaged tissue surrounding the site of injury)
- Temporal summation (increased pain perception with repetitive stimulation)
- After-sensations (persistent pain following cessation of a stimulus)
- Referred pain and widespread pain [3,8]

3.2. Cellular and Molecular Mechanisms

At the cellular level, central sensitization involves multiple neuroplastic changes that enhance nociceptive processing in the dorsal horn of the spinal cord and at supraspinal sites [4].

3.2.1. Glutamatergic Signaling and NMDA Receptor Activation

A primary mechanism underlying central sensitization is the enhanced activation of N-methyl-D-aspartate (NMDA) receptors in second-order neurons within the dorsal horn [9]. Under normal conditions, NMDA receptors are blocked by magnesium ions at resting membrane potential. However, sustained nociceptive input leads to sufficient depolarization to remove this magnesium block, allowing calcium influx through the receptor channel.

Several key events occur following NMDA receptor activation:

- Influx of calcium ions triggers calcium-dependent intracellular signaling cascades
- Activation of protein kinases, including protein kinase C (PKC), calcium/calmodulin-dependent protein kinase II (CaMKII), and extracellular signal-regulated kinase (ERK)
- Phosphorylation of NMDA and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, increasing their activity and membrane insertion
- Upregulation of the trafficking of AMPA receptors to the postsynaptic membrane, enhancing synaptic efficacy [4,10]

3.2.2. Transcriptional and Translational Changes

 doi:10.20944/preprints202503.1506.v1

Sustained activation of protein kinases leads to the phosphorylation of transcription factors such as cAMP response element-binding protein (CREB) and nuclear factor kappa B (NF-κB), driving the expression of genes that contribute to neuronal hyperexcitability [8].

These transcriptional changes include:

- Upregulation of genes encoding for pronociceptive neurotransmitters and their receptors
- Increased expression of voltage-gated ion channels, enhancing neuronal excitability
- Production of cytokines and growth factors that further modulate synaptic transmission
- Changes in the expression of neuropeptides, including substance P and calcitonin gene-related peptide (CGRP) [4]

3.2.3. Synaptic Facilitation and Potentiation

Central sensitization involves both homosynaptic potentiation (increased synaptic strength at previously activated synapses) and heterosynaptic facilitation (enhanced transmission at non-activated synapses) [102].

Long-term potentiation (LTP) in nociceptive pathways shares mechanistic similarities with LTP in hippocampal learning circuits, suggesting that central sensitization represents a form of pain memory [52]. This pain memory manifests as increased synaptic efficacy in nociceptive neurons, contributing to the persistence of pain even after the initial stimulus has resolved.

3.3. Disinhibition and Loss of Descending Inhibition

Central sensitization is not only characterized by enhanced excitatory transmission but also by impaired inhibitory control [12].

3.3.1. Spinal Disinhibition

In the dorsal horn, GABAergic and glycinergic interneurons provide critical inhibitory control over nociceptive transmission. Under pathological conditions, this inhibitory control can be compromised through:

- Reduced expression of the potassium-chloride cotransporter KCC2, disrupting chloride homeostasis and diminishing the efficacy of GABA-mediated inhibition
- Excitotoxic death of inhibitory interneurons following peripheral nerve injury
- Reduced release of inhibitory neurotransmitters
- Altered expression of GABA and glycine receptors [11,12]

3.3.2. Impaired Descending Inhibition

Descending pain modulatory pathways originating from the periaqueductal gray (PAG), rostral ventromedial medulla (RVM), and locus coeruleus can facilitate or inhibit nociceptive transmission at the spinal level. In chronic pain conditions, there is evidence for:

- Reduced efficacy of descending inhibitory pathways mediated by noradrenaline and serotonin
- Enhanced activity in descending facilitatory pathways
- Altered endogenous opioid signaling
- Dysfunction in the diffuse noxious inhibitory control (DNIC) system, now referred to as conditioned pain modulation (CPM) [13,14]

3.4. Glial Activation and Neuroinflammation

Mounting evidence indicates that non-neuronal cells, particularly microglia and astrocytes, play crucial roles in the initiation and maintenance of central sensitization [15].

3.4.1. Microglial Activation

 doi:10.20944/preprints202503.1506.v1

Peripheral nerve injury or inflammation triggers microglial activation in the spinal cord through various signaling pathways, including:

- Release of ATP binding to P2X4 and P2X7 receptors on microglia
- Activation of toll-like receptors (TLRs) by damage-associated molecular patterns (DAMPs)
- Chemokine signaling, particularly involving CX3CL1 (fractalkine) and its receptor CX3CR1 [15,16]

Activated microglia release proinflammatory cytokines (IL-1β, IL-6, TNF-α), chemokines, and brain-derived neurotrophic factor (BDNF), which enhance neuronal excitability and contribute to disinhibition [115].

3.4.2. Astrocytic Involvement

Astrocytes also become activated in chronic pain conditions, though typically with a more delayed time course compared to microglia. Activated astrocytes:

- Release proinflammatory cytokines and chemokines
- Express increased levels of glial fibrillary acidic protein (GFAP)
- Show altered glutamate uptake, potentially leading to excitotoxicity
- Release factors that modulate synaptic transmission and neuronal excitability [15,40]

3.4.3. Neuroinflammatory Cascades

The interaction between activated glia and neurons establishes a self-perpetuating cycle of neuroinflammation that contributes to the persistence of central sensitization:

- Proinflammatory cytokines enhance NMDA receptor function and AMPA receptor trafficking
- TNF-α increases presynaptic glutamate release and decreases GABA-mediated inhibition
- IL-1β activates protein kinases that phosphorylate ion channels and receptors
- BDNF released from microglia downregulates KCC2 expression, disrupting chloride homeostasis and compromising GABAergic inhibition [15,17]

3.5. Supraspinal Mechanisms and Brain Connectivity

Central sensitization is not confined to the spinal cord but also involves substantial changes in supraspinal processing of pain signals and alterations in brain connectivity patterns [18].

3.5.1. Thalamic Changes

The thalamus serves as a critical relay and processing hub for nociceptive information. In chronic pain conditions:

- Altered firing patterns and bursting activity in thalamic neurons have been observed
- Changes in thalamocortical connections modify sensory discrimination and affective processing of pain
- Thalamic disinhibition contributes to increased throughput of nociceptive signals to cortical regions [19,20]

3.5.2. Cortical Reorganization

Functional and structural changes in cortical regions involved in pain processing include:

- Shrinkage in gray matter volume in regions such as the insula, anterior cingulate cortex (ACC), and prefrontal cortex
- Expansion of cortical representation areas for painful body regions
- Altered excitability in primary (S1) and secondary (S2) somatosensory cortices
- Reorganization of neural circuits in the default mode network and salience network [18,21]

 doi:10.20944/preprints202503.1506.v1

3.5.3. Changes in Brain Connectivity

Advanced neuroimaging techniques have revealed alterations in functional and structural connectivity patterns in chronic pain conditions:

- Enhanced connectivity between brain regions involved in pain processing
- Disrupted connectivity between regulatory regions and pain-processing areas
- Altered balance between ascending nociceptive pathways and descending modulatory systems
- Changes in the dynamic interaction between networks involved in sensory, affective, and cognitive dimensions of pain [21,22]

4. Clinical Manifestations and Assessment of Central Sensitization

4.1. Clinical Features of Central Sensitization

Central sensitization manifests through various clinical features that extend beyond the traditional concept of pain related directly to tissue damage:

4.1.1. Generalized Hyperalgesia and Allodynia

Patients with central sensitization typically exhibit heightened sensitivity to painful stimuli (hyperalgesia) and pain in response to normally non-painful stimuli (allodynia). These phenomena can be observed:

- At the site of primary injury (primary hyperalgesia)
- In uninjured areas surrounding the primary site (secondary hyperalgesia)
- In remote body regions unrelated to the initial injury (widespread hyperalgesia) [3]
- Multiple studies have documented generalized pressure pain hypersensitivity, heightened responses to heat and cold stimuli, and mechanical allodynia in conditions such as fibromyalgia, chronic whiplash-associated disorders, and osteoarthritis [4,23].

4.1.2. Expanded Receptive Fields

The expansion of receptive fields represents a hallmark of central sensitization, wherein nociceptive neurons in the dorsal horn respond to stimuli applied to a larger area than under normal conditions [3]. Clinically, this manifests as:

- Referred pain (pain perceived in areas distant from the source)
- Radiation of pain beyond the territory of the affected nerve or tissue
- Widespread, poorly localized pain [23,89]

4.1.3. Temporal Summation and After-Sensations

Temporal summation refers to the progressive increase in pain perception during repeated or sustained stimulation, even when stimulus intensity remains constant. This phenomenon:

- Reflects the "wind-up" of dorsal horn neurons due to C-fiber barrage
- Is significantly enhanced in patients with central sensitization
- Often accompanies prolonged after-sensations (pain that persists after stimulus cessation) [5,112]

Studies in fibromyalgia, tension-type headache, and temporomandibular disorders have consistently demonstrated exaggerated temporal summation in response to repetitive mechanical or thermal stimuli [76,112]

4.1.4. Sensory Hypersensitivity and Intolerance

Beyond pain, central sensitization is associated with heightened sensitivity to multiple sensory stimuli:

 doi:10.20944/preprints202503.1506.v1

- Photophobia (light sensitivity)
- Phonophobia (sensitivity to sounds)
- Osmophobia (sensitivity to odors)
- Chemical sensitivity
- Intolerance to weather changes [5]

This multi-sensory hypersensitivity suggests involvement of central mechanisms that extend beyond nociceptive pathways, potentially affecting multisensory integration processes.

4.1.5. Impaired Conditioned Pain Modulation

Conditioned pain modulation (CPM), formerly known as diffuse noxious inhibitory controls (DNIC), represents an endogenous pain inhibitory system wherein "pain inhibits pain" [124]. Patients with central sensitization frequently exhibit:

- Reduced efficacy of CPM
- Inability to activate endogenous inhibitory pathways in response to a conditioning painful stimulus
- In some cases, facilitation rather than inhibition in response to conditioning stimuli [14]

Impaired CPM has been documented in fibromyalgia, irritable bowel syndrome, temporomandibular disorders, and certain types of headaches, suggesting deficient endogenous pain control as a common feature across these conditions [111,124].

4.2. Clinical Assessment and Diagnostic Approaches

Given the subjective nature of pain and the absence of definitive biomarkers, diagnosing central sensitization remains challenging. However, several clinical tools and experimental paradigms have been developed to identify its presence and severity:

4.2.1. Quantitative Sensory Testing (QST)

QST provides a comprehensive evaluation of sensory function through standardized stimuli and psychophysical methods:

- Pressure pain thresholds using algometers
- Thermal pain thresholds using thermodes
- Mechanical pain sensitivity using von Frey filaments or pin-prick stimuli
- Temporal summation using repeated stimuli
- Conditioned pain modulation paradigms [100,129]

Widespread reductions in pain thresholds across multiple testing sites, enhanced temporal summation, and impaired CPM are considered indicative of central sensitization [5].

4.2.2. Central Sensitization Inventory (CSI)

The CSI is a validated self-report questionnaire designed to assess symptoms associated with central sensitization [82]. The instrument:

- Contains 25 items related to somatic and emotional symptoms
- Provides a severity score ranging from 0 to 100
- Has demonstrated good psychometric properties, including test-retest reliability and construct validity
- Shows associations with experimental pain measures and treatment outcomes [87,107]

A CSI score ≥40 is considered indicative of clinically significant central sensitization [88].

4.2.3. Clinical Recognition of Central Sensitization

 doi:10.20944/preprints202503.1506.v1

Nijs and colleagues [91] proposed clinical criteria for identifying central sensitization in patients with musculoskeletal pain:

- Pain experiences disproportionate to the nature and extent of injury or pathology
- Diffuse pain distribution pattern
- Hypersensitivity to various stimuli not limited to the region of primary complaint
- Hypersensitivity unrelated to the activity of the affected segment
- Poor response to analgesics, NSAIDS, and peripheral interventions (e.g., injections)
- Strong association with stress, emotions, and cognitive factors [91]

4.2.4. Neuroimaging Approaches

Advanced neuroimaging techniques provide insights into the central mechanisms underlying sensitization:

- Functional MRI (fMRI) reveals altered activation patterns in pain-processing regions
- Resting-state fMRI demonstrates changes in functional connectivity
- Magnetic resonance spectroscopy (MRS) shows alterations in brain neurochemistry, including glutamate and GABA levels
- Diffusion tensor imaging (DTI) identifies structural connectivity changes in white matter tracts [24,50]

While neuroimaging findings have enhanced our understanding of central sensitization, their clinical utility in individual diagnosis remains limited due to cost, availability, and lack of standardized protocols.

5. Chronic Pain Conditions Associated with Central Sensitization

5.1. Fibromyalgia

Fibromyalgia is perhaps the prototypical central sensitization syndrome, characterized by chronic widespread pain, fatigue, sleep disturbances, and cognitive dysfunction [23].

5.1.1. Evidence for Central Sensitization in Fibromyalgia

Multiple lines of evidence implicate central sensitization in fibromyalgia:

- Widespread reductions in pressure and thermal pain thresholds
- Enhanced temporal summation of pain
- Impaired conditioned pain modulation
- Altered brain activation patterns in response to painful and non-painful stimuli
- Abnormal levels of neurotransmitters and neuromodulators in cerebrospinal fluid, including elevated substance P and glutamate, and reduced levels of inhibitory neurotransmitters [23,24]

Neuroimaging studies have revealed:

- Augmented brain responses to painful stimuli in regions such as the insula, anterior cingulate cortex, and prefrontal cortex
- Altered resting-state functional connectivity, particularly in networks involved in pain processing and modulation
- Changes in gray matter volume in pain-related brain regions [25]

5.1.2. Clinical Implications

The recognition of central sensitization in fibromyalgia has led to:

- Shift from peripheral to centrally-acting treatment approaches
- Focus on medications targeting neurotransmitter imbalances (e.g., duloxetine, pregabalin)
- Implementation of non-pharmacological interventions addressing central mechanisms, such as exercise, cognitive-behavioral therapy, and neurostimulation [23]

 doi:10.20944/preprints202503.1506.v1

5.2. Neuropathic Pain

Neuropathic pain arises from lesions or diseases affecting the somatosensory nervous system and often involves central sensitization mechanisms [26].

5.2.1. Central Mechanisms in Neuropathic Pain

While neuropathic pain originates from neural damage, central sensitization contributes significantly to its maintenance and clinical presentation:

- Spinal cord hyperexcitability following peripheral nerve injury
- Microglial and astrocytic activation in the spinal cord
- Disinhibition due to loss of GABAergic interneurons
- Altered descending modulation from brainstem centers
- Maladaptive cortical reorganization [4,26]

Animal models of neuropathic pain demonstrate:

- Upregulation of voltage-gated sodium and calcium channels
- Enhanced NMDA receptor phosphorylation
- Phenotypic changes in primary afferents, with Aβ fibers expressing neuropeptides typically associated with C-fibers
- Progressive glial activation that parallels the development of pain behaviors [27,28]

5.2.2. Clinical Implications

The involvement of central sensitization in neuropathic pain explains:

- The presence of pain in areas with no demonstrable pathology
- The limited efficacy of interventions targeting only the peripheral lesion
- The beneficial effects of centrally-acting medications such as gabapentinoids, antidepressants, and NMDA receptor antagonists
- The utility of neuromodulatory approaches [26,39]

5.3. Complex Regional Pain Syndrome (CRPS)

CRPS represents a multifactorial condition characterized by regional pain, sensory abnormalities, autonomic dysfunction, motor impairments, and trophic changes [29].

5.3.1. Central Sensitization Components in CRPS

Central sensitization in CRPS is evidenced by:

- Generalized hyperalgesia and allodynia extending beyond the affected limb
- Enhanced temporal summation and after-sensations
- Impaired conditioned pain modulation
- Cortical reorganization, with altered representation of the affected limb in the somatosensory cortex
- Spread of symptoms to other limbs in some cases [29,30]

Neuroimaging findings include:

- Changes in gray matter volume in pain-processing regions
- Altered activity in motor cortical areas
- Reorganization of somatosensory maps
- Disrupted functional connectivity patterns [31]

5.3.2. Clinical Implications

Recognition of central mechanisms in CRPS has informed treatment approaches:

- Early intervention to prevent entrenchment of central sensitization

 doi:10.20944/preprints202503.1506.v1

- Use of centrally-acting medications alongside peripheral interventions
- Implementation of graded motor imagery and mirror therapy to address cortical reorganization
- Application of neuromodulatory techniques targeting central processes [94,106]

5.4. Chronic Primary Headache Disorders

Migraine, tension-type headache, and other primary headache disorders involve central sensitization mechanisms that contribute to their clinical presentation and chronification [32].

5.4.1. Central Sensitization in Headache Disorders

In migraine, central sensitization manifests as:

- Allodynia during attacks, reflecting sensitization of thalamic neurons
- Persistent interictal hypersensitivity in chronic migraine
- Enhanced cortical excitability and reduced habituation to sensory stimuli
- Altered pain modulation with deficient inhibitory control [33,32]

In tension-type headache:

- Increased pericranial tenderness and generalized pressure hyperalgesia
- Enhanced temporal summation to repetitive stimuli
- Impaired conditioned pain modulation
- Sensitization at multiple levels of the neuraxis [34,35]

5.4.2. Clinical Implications

The recognition of central sensitization in headache disorders has led to:

- Emphasis on preventing sensitization through early intervention in acute attacks
- Use of preventive medications targeting central mechanisms (antidepressants, anticonvulsants)
- Application of neuromodulatory approaches such as transcranial magnetic stimulation and transcranial direct current stimulation
- Implementation of non-pharmacological interventions addressing central processes [32]

5.5. Visceral Pain Syndromes

Functional gastrointestinal disorders such as irritable bowel syndrome (IBS) and other visceral pain conditions often involve central sensitization mechanisms [36].

5.5.1. Central Sensitization in Visceral Pain

Evidence for central sensitization in visceral pain syndromes includes:

- Visceral hyperalgesia and allodynia
- Referred hyperalgesia in somatic structures sharing spinal innervation with visceral organs
- Enhanced brain responses to visceral stimuli
- Comorbidity with other central sensitivity syndromes (e.g., fibromyalgia, chronic fatigue syndrome)
- Stress-induced symptom exacerbation, reflecting altered central processing [36,37]

Neuroimaging studies in IBS have demonstrated:

- Altered activation patterns in the insula, anterior cingulate cortex, and prefrontal regions
- Changes in brain structure, including gray matter density
- Abnormal connectivity in networks involved in visceral sensation and emotional processing [64,84]

5.5.2. Clinical Implications

Understanding central sensitization in visceral pain has informed:

 doi:10.20944/preprints202503.1506.v1

- Development of centrally-acting treatments for functional gastrointestinal disorders
- Recognition of the limited utility of peripheral interventions in isolation
- Implementation of psychological approaches addressing central processes, such as cognitive-behavioral therapy and gut-directed hypnotherapy
- Application of neuromodulatory techniques targeting central mechanisms [36,38]

6. Treatment Approaches Targeting Central Sensitization

6.1. Pharmacological Interventions

Various pharmacological agents target different aspects of central sensitization, with varying degrees of efficacy across pain conditions [39].

6.1.1. NMDA Receptor Antagonists

Given the critical role of NMDA receptors in central sensitization, antagonists of these receptors represent logical therapeutic targets:

Ketamine:

- Provides analgesia by blocking NMDA receptors, thereby inhibiting glutamatergic transmission
- Shows efficacy in various chronic pain conditions, including CRPS, fibromyalgia, and refractory neuropathic pain
- Administered in sub-anesthetic doses via intravenous, oral, or topical routes
- Requires careful monitoring due to psychomimetic side effects and potential for abuse [40,41]

Several clinical trials have demonstrated the effectiveness of ketamine infusions in reducing pain intensity and improving function in patients with CRPS and fibromyalgia, with effects lasting weeks to months after treatment cessation [40]

Memantine:

- Non-competitive NMDA receptor antagonist with better tolerability than ketamine
- Shows modest efficacy in neuropathic pain and fibromyalgia
- Better safety profile but potentially less effective than ketamine
- May be beneficial as an adjunct to other therapies [95,98]

Dextromethorphan:

- NMDA receptor antagonist commonly used as a cough suppressant
- Combined with quinidine (to inhibit metabolism) in the FDA-approved product Nuedexta
- Limited evidence for efficacy in central sensitization conditions
- May offer benefit in select patients with neuropathic pain [103]

6.1.2. Gabapentinoids

Gabapentin and pregabalin bind to the α2δ subunit of voltage-gated calcium channels, reducing calcium influx and subsequent release of excitatory neurotransmitters:

Pregabalin:

- FDA-approved for fibromyalgia, diabetic peripheral neuropathy, and postherpetic neuralgia
- Reduces calcium influx into presynaptic terminals, decreasing glutamate release
- Demonstrates efficacy in multiple central sensitization conditions
- Common side effects include dizziness, somnolence, and weight gain [42,43]

A meta-analysis of 8 randomized controlled trials involving 3,546 fibromyalgia patients reported that pregabalin significantly reduced pain and improved sleep quality compared to placebo, with a number needed to treat (NNT) of 9.5 for 50% pain reduction [130].

Gabapentin:

- Similar mechanism to pregabalin but with different pharmacokinetics
- Efficacious in various neuropathic pain conditions

 doi:10.20944/preprints202503.1506.v1

- Less consistent evidence for efficacy in fibromyalgia
- Requires higher doses and more frequent administration compared to pregabalin [79,81]

6.1.3. Antidepressants

Antidepressants modulate central pain processing through effects on monoaminergic systems, particularly serotonin and norepinephrine pathways involved in descending pain inhibition:

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs):

- Duloxetine and milnacipran are FDA-approved for fibromyalgia
- Enhance descending inhibitory control by increasing synaptic levels of serotonin and norepinephrine
- Demonstrate efficacy in various central sensitization conditions, including fibromyalgia, neuropathic pain, and chronic low back pain
- Common side effects include nausea, dry mouth, and dizziness [6,44]

A network meta-analysis of 18 randomized controlled trials with 7,903 participants found duloxetine to be significantly more effective than milnacipran and pregabalin for pain reduction in fibromyalgia, particularly in patients with comorbid depression [68].

Tricyclic Antidepressants (TCAs):

- Amitriptyline has long been used for fibromyalgia and neuropathic pain
- Acts on multiple neurotransmitter systems and ion channels
- Efficacy supported by numerous clinical trials, especially for fibromyalgia and headache disorders
- Limited by anticholinergic side effects and potential toxicity in overdose [45,80]

6.1.4. Anti-inflammatory Agents and Cytokine Inhibitors

Given the role of neuroinflammation in central sensitization, agents targeting inflammatory processes may offer therapeutic benefit:

Microglia Inhibitors:

- Low-dose naltrexone reduces microglial activation and shows promise in fibromyalgia
- Minocycline inhibits microglial activation and demonstrates efficacy in preclinical models and preliminary clinical studies
- Ibudilast, a phosphodiesterase inhibitor with anti-inflammatory properties, is under investigation for various pain conditions [72,131]

A double-blind, placebo-controlled trial of low-dose naltrexone (4.5 mg daily) in fibromyalgia demonstrated significant improvements in pain, fatigue, and overall wellbeing compared to placebo, with minimal side effects [131]

Cytokine Inhibitors:

- Biologics targeting TNF-α, IL-6, and other cytokines show mixed results in chronic pain conditions
- More effective in inflammatory conditions with peripheral components than in primary central sensitization syndromes
- High cost and potential adverse effects limit widespread use [14]

6.1.5. Novel and Emerging Pharmacological Approaches

Several novel approaches targeting central sensitization mechanisms are under investigation:

Sigma-1 Receptor Antagonists:

- Fluvoxamine and the newer agent E-52862 modulate NMDA receptor activity through sigma-1 receptors
- Show promise in preclinical models and early clinical trials for neuropathic pain
- May offer a more favorable side effect profile compared to direct NMDA antagonists [59]

 doi:10.20944/preprints202503.1506.v1

T-type Calcium Channel Blockers:

- Ethosuximide and newer selective agents target T-type calcium channels in nociceptive pathways
- Demonstrate efficacy in preclinical models of neuropathic pain
- Clinical evidence remains limited but encouraging [13,31]

Epigenetic Modulators:

- Histone deacetylase inhibitors and DNA methyltransferase inhibitors modify gene expression related to pain processing
- Show promise in preclinical studies for reversing established hyperalgesia
- Represent a potential approach for addressing the persistence of central sensitization [27,128]

6.2. Non-Pharmacological Interventions

Non-pharmacological approaches play a crucial role in managing central sensitization by targeting various mechanisms, often with fewer side effects than medications [46].

6.2.1. Education and Pain Neuroscience Education

Education about pain mechanisms represents a fundamental component of managing central sensitization:

Pain Neuroscience Education (PNE):

- Involves explaining the neurophysiological mechanisms of pain, particularly central sensitization
- Aims to shift patients' understanding from a tissue-damage model to a central nervous system model
- Reduces fear, catastrophizing, and maladaptive pain behaviors
- Enhances adherence to active treatments [65,132]

A systematic review of 13 randomized controlled trials found that PNE significantly reduces pain, disability, catastrophizing, and limited physical movement in various chronic pain conditions, with moderate to large effect sizes [47].

Cognitive-Behavioral Approaches:

- Cognitive-behavioral therapy (CBT) addresses maladaptive thoughts, emotions, and behaviors related to pain
- Acceptance and commitment therapy (ACT) focuses on psychological flexibility and engagement in valued activities despite pain
- Both approaches demonstrate efficacy in reducing pain, improving function, and enhancing quality of life in central sensitization conditions [45,48]

A network meta-analysis of 75 randomized controlled trials involving 9,401 patients with fibromyalgia found that CBT, particularly when delivered in group settings, was superior to other psychological interventions for reducing pain, with sustained benefits at long-term follow-up [10].

6.2.2. Exercise and Physical Activity

Exercise represents one of the most effective interventions for central sensitization by modulating pain processing at multiple levels:

Aerobic Exercise:

- Activates endogenous opioid and non-opioid pain inhibitory mechanisms
- Reduces inflammatory markers associated with central sensitization
- Improves conditioned pain modulation efficacy
- Demonstrates consistent benefits across various chronic pain conditions [48]

 doi:10.20944/preprints202503.1506.v1

A Cochrane review of 13 randomized controlled trials with 839 participants concluded that aerobic exercise improves physical function and may reduce pain intensity and fatigue in fibromyalgia, with moderate-quality evidence [133].

Resistance Training:

- Activates endogenous analgesia through different mechanisms than aerobic exercise
- Improves strength, function, and body composition
- Shows efficacy in fibromyalgia, osteoarthritis, and chronic widespread pain
- May complement aerobic exercise in comprehensive programs [49]

Graded Activity and Exposure:

- Involves progressively increasing activity levels based on time or quotas rather than pain
- Addresses fear-avoidance behaviors that contribute to pain perpetuation
- Demonstrates efficacy in various chronic pain conditions, particularly when combined with cognitive-behavioral approaches [69,70]

6.2.3. Mind-Body Approaches

Various mind-body interventions modulate central pain processing and demonstrate efficacy in central sensitization conditions:

Mindfulness-Based Interventions:

- Mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT) enhance pain acceptance and reduce catastrophizing
- Modify brain regions involved in pain processing, including the anterior cingulate cortex and insula
- Show efficacy in fibromyalgia, headache disorders, and other chronic pain conditions [126]

A meta-analysis of 11 randomized controlled trials with 1,307 participants found that mindfulness meditation significantly reduced pain intensity compared to treatment as usual, with moderate effect sizes [134].

Yoga and Tai Chi:

- Combine gentle movement, breathing regulation, and meditative focus
- Improve physical function, psychological wellbeing, and sleep quality
- Demonstrate benefits in fibromyalgia, osteoarthritis, and headache disorders
- May address multiple aspects of central sensitization simultaneously [62]

Biofeedback and Relaxation Techniques:

- Heart rate variability biofeedback improves autonomic regulation
- EMG biofeedback reduces muscle tension and enhances body awareness
- Progressive muscle relaxation and autogenic training reduce sympathetic arousal
- These approaches show particular benefit in headache disorders, fibromyalgia, and temporomandibular disorders [42,86]

6.3. Neuromodulation and Invasive Interventions

Neuromodulation techniques directly target neural circuits involved in central sensitization and may offer benefit when other approaches prove insufficient [26]

6.3.1. Non-Invasive Brain Stimulation

Several non-invasive brain stimulation techniques modulate cortical excitability and pain processing:

Transcranial Magnetic Stimulation (TMS):

- Repetitive TMS (rTMS) over the primary motor cortex or dorsolateral prefrontal cortex modulates pain processing networks
- High-frequency stimulation typically produces analgesic effects

 doi:10.20944/preprints202503.1506.v1

- FDA-approved for migraine prevention and shows promise in fibromyalgia and neuropathic pain
- Requires specialized equipment and trained personnel [50,67]

A meta-analysis of 27 randomized controlled trials with 655 participants reported that high-frequency rTMS of the motor cortex significantly reduced neuropathic pain compared to sham stimulation, with a moderate effect size [67].

Transcranial Direct Current Stimulation (tDCS):

- Applies weak electrical currents to modulate cortical excitability
- Anodal stimulation of the primary motor cortex produces analgesic effects in various pain conditions
- More accessible and less expensive than TMS, with potential for home use
- Effects are typically modest and may require maintenance sessions [38,50]

Cranial Electrotherapy Stimulation (CES):

- Applies pulsed, low-intensity electrical currents via electrodes placed on the earlobes, mastoid processes, or temples
- FDA-approved for insomnia, depression, and anxiety
- Shows mixed results for pain reduction in fibromyalgia and other central sensitization conditions
- Mechanism remains poorly understood despite long history of use [114]

6.3.2. Spinal Cord Stimulation (SCS)

SCS modulates pain transmission at the spinal level through implanted electrodes:
Conventional SCS:

- Delivers electrical pulses that activate large-diameter fibers, indirectly inhibiting nociceptive transmission (gate control mechanism)
- Established efficacy in complex regional pain syndrome and failed back surgery syndrome
- Limited evidence for primary central sensitization syndromes like fibromyalgia
- Requires surgical implantation and carries risks of infection, lead migration, and hardware failure [26,119]

Novel SCS Paradigms:

- High-frequency (10 kHz) stimulation does not produce paresthesias and may more effectively modulate glial activation
- Burst stimulation mimics natural neuronal firing patterns and may better engage supraspinal mechanisms
- Dorsal root ganglion stimulation provides more focused modulation of specific dermatomes
- These newer approaches demonstrate improved efficacy in some pain conditions compared to conventional SCS [25,57]

A randomized controlled trial comparing high-frequency (10 kHz) SCS to conventional SCS in 198 patients with chronic back and leg pain found that high-frequency stimulation provided superior pain relief (greater than 50% reduction) in 84.5% of participants compared to 43.8% with conventional SCS [57].

6.3.3. Deep Brain Stimulation (DBS)

DBS involves surgical implantation of electrodes in specific brain regions:

- Targets include the periventricular/periaqueductal gray, sensory thalamus, and anterior cingulate cortex
- Reserved for intractable cases due to invasiveness and potential complications
- Shows promise in select cases of chronic neuropathic pain and cluster headache

 doi:10.20944/preprints202503.1506.v1

- Mechanism involves modulation of both sensory-discriminative and affective-motivational aspects of pain [12,39]

A systematic review of 22 studies involving 162 patients with various chronic pain conditions reported that approximately 60% of patients experienced significant long-term pain reduction with DBS, though publication bias may have influenced these findings [39]

6.4. Integrative and Multimodal Approaches

Given the multidimensional nature of central sensitization, integrative approaches combining multiple treatment modalities often yield superior outcomes compared to monotherapy [117]

6.4.1. Interdisciplinary Pain Rehabilitation Programs

Comprehensive programs integrating multiple disciplines demonstrate efficacy in managing central sensitization:

- Combine medical management, physical therapy, occupational therapy, and psychological interventions
- Emphasize active patient participation and self-management strategies
- Focus on functional restoration rather than pain elimination
- Typically delivered in intensive outpatient or inpatient settings [41]

A systematic review of 41 randomized controlled trials with 6,858 participants concluded that interdisciplinary rehabilitation programs were more effective than single-discipline approaches for improving pain, function, and return to work in chronic pain conditions, with sustained benefits at long-term follow-up [135]

6.4.2. Tailored Multimodal Approaches

Personalized treatment plans addressing multiple aspects of central sensitization may enhance outcomes:

- Combination of pharmacological agents targeting different mechanisms (e.g., SNRI plus gabapentinoid)
- Integration of appropriate exercise modalities with psychological interventions
- Addition of neuromodulation techniques when appropriate
- Individualization based on patient characteristics, preferences, and response to treatment [18,117]

6.4.3. Complementary and Integrative Health Approaches

Various complementary approaches show promise in managing central sensitization:
Acupuncture:

- Activates endogenous opioid and non-opioid pain modulatory systems
- Modulates inflammatory markers and autonomic function
- Shows efficacy in fibromyalgia, headache disorders, and osteoarthritis
- May enhance the effects of conventional treatments when used as an adjunct [71]

A Cochrane review of 29 randomized controlled trials with 17,922 participants concluded that acupuncture was superior to both sham acupuncture and no acupuncture for chronic pain conditions, with persistent benefits at 12-month follow-up [118]

Massage Therapy:

- Reduces muscle tension and enhances local blood flow
- Modulates inflammatory markers and autonomic arousal
- Shows short-term benefits for pain and mood in various conditions
- May serve as a useful adjunct to more active interventions [22,35]

 doi:10.20944/preprints202503.1506.v1

Medical Cannabis and Cannabinoids:

- Modulate pain processing through interactions with the endocannabinoid system
- Show varying degrees of efficacy across different pain conditions
- Generally, more effective for neuropathic than nociceptive pain
- Limited by side effects, regulatory barriers, and inconsistent product quality [1,47]

A systematic review of 47 randomized controlled trials with 4,755 participants found moderate-quality evidence supporting cannabinoids for chronic pain, with 30% of patients achieving at least 30% pain reduction compared to 20% with placebo [1]

7. Future Directions and Emerging Concepts

7.1. Personalized Medicine Approaches

The heterogeneity of central sensitization manifestations across individuals and conditions necessitates personalized approaches to diagnosis and treatment [34]

7.1.1. Pain Phenotyping

Identifying specific pain phenotypes may enhance treatment targeting:

- Sensory phenotyping using quantitative sensory testing to identify patterns of sensitization
- Psychological phenotyping based on cognitive-affective profiles
- Sleep, fatigue, and autonomic phenotyping to capture broader symptom clusters
- Integration of multiple dimensions to create comprehensive phenotypic profiles [8,34]

A cluster analysis of QST parameters in 902 patients with neuropathic pain identified three distinct sensory phenotypes: sensory loss (42%), thermal hyperalgesia (33%), and mechanical hyperalgesia (24%). These phenotypes showed different responses to treatment, with opioids being more effective for the sensory loss phenotype and sodium channel blockers for the hyperalgesia phenotypes [8]

7.1.2. Biomarkers for Central Sensitization

Development of reliable biomarkers may facilitate diagnosis and treatment selection:

- Neuroimaging markers, including functional connectivity patterns and neurochemical profiles
- Quantitative sensory testing parameters, particularly temporal summation and conditioned pain modulation
- Inflammatory markers and cytokine profiles
- Genetic and epigenetic markers related to pain processing
- Autonomic and stress response indicators [44,46]

7.1.3. Pharmacogenomics

Genetic variations influence response to analgesic medications:

- Polymorphisms in genes encoding drug-metabolizing enzymes (e.g., CYP2D6) affect response to many analgesics
- Variations in opioid receptor genes predict response to opioid analgesics
- Polymorphisms in serotonin and norepinephrine transporter genes influence response to antidepressants
- Integration of genetic information may guide more effective treatment selection [58,116]

7.3. Novel Therapeutic Targets

Advances in understanding central sensitization mechanisms reveal new potential therapeutic targets:

 doi:10.20944/preprints202503.1506.v1

7.2.1. Glial Modulators

Targeting glial activation offers promise for addressing neuroinflammatory aspects of central sensitization:

- Toll-like receptor antagonists reduce microglial activation in preclinical models
- Colony-stimulating factor 1 receptor inhibitors selectively target microglia
- Adenosine A2A receptor agonists modify astrocytic function
- P2X4 and P2X7 receptor antagonists block purinergic signaling involved in microglial activation [51,55]

7.2.2. Epigenetic Approaches

Modulating epigenetic mechanisms may address the persistence of central sensitization:

- Histone deacetylase inhibitors show promise in reversing established hyperalgesia in preclinical models
- DNA methyltransferase inhibitors normalize aberrant gene expression patterns
- Non-coding RNAs, particularly microRNAs, offer potential for selective modulation of pain pathways
- Small molecule epigenetic modulators with improved specificity are under development [27,93]

7.2.3. Neuroplasticity-Targeting Interventions

Novel approaches targeting maladaptive neuroplasticity may enhance treatment efficacy:

- BDNF-TrkB signaling modulators affect neuronal connectivity and excitability
- Matrix metalloproteinase inhibitors modify extracellular matrix remodeling involved in structural plasticity
- Selective targeting of NR2B-containing NMDA receptors may provide analgesia with fewer side effects
- Optogenetic and chemogenetic approaches offer unprecedented specificity in preclinical models [97,99]

7.3. Advanced Neuromodulation Approaches

Technological advances are enhancing neuromodulation approaches for central sensitization:

7.3.1. Closed-Loop Systems

Adaptive stimulation systems that respond to physiological signals:

- Recording and stimulation capabilities in a single device
- Adjustment of stimulation parameters based on neural activity or biomarkers
- Potential for more precise and efficient neuromodulation
- Early evidence of efficacy in epilepsy, with pain applications under development [105,110]

7.3.2. Noninvasive Focused Ultrasound

Ultrasound-based neuromodulation offers potential advantages:

- Capable of reaching deep brain structures non-invasively
- Provides higher spatial resolution than other non-invasive techniques
- Can be used for both excitation and inhibition of neural activity
- Early clinical studies show promise for pain conditions [30]

 doi:10.20944/preprints202503.1506.v1

7.3.3. Network-Based Approaches

Targeting neural networks rather than specific regions:

- Identification of pain connectomes through advanced neuroimaging
- Simultaneous or sequential stimulation of multiple nodes within pain networks
- Personalized targeting based on individual network abnormalities
- Potential for more comprehensive modulation of pain processing [22]

7.4. Virtual Reality and Digital Therapeutics

Digital approaches offer novel ways to address central sensitization:

7.4.1. Virtual Reality for Pain Modulation

Immersive environments modulate pain processing:

- Distraction-based analgesia through multisensory engagement
- Graded exposure to movement and activity in virtual environments
- Modification of body perception through virtual embodiment
- Growing evidence for efficacy in acute and chronic pain conditions [56]

A systematic review of 17 studies found that virtual reality interventions significantly reduced pain intensity in various chronic pain conditions, with moderate to large effect sizes and minimal adverse effects [136]

7.4.2. Digital Therapeutics and Mobile Health

Technology-based interventions expand treatment access and adherence:

- Smartphone-based pain management programs delivering cognitive-behavioral approaches
- Wearable devices monitoring activity and providing real-time feedback
- Remote monitoring enabling personalized adjustments to treatment plans
- Digital biomarkers capturing real-world pain experiences and treatment responses [37,75]

7.4.3. Brain-Computer Interfaces

Direct brain-computer communication offers novel therapeutic avenues:

- Neurofeedback training targeting specific brain regions or networks involved in pain processing
- Thought-controlled prosthetics and assistive devices for patients with comorbid motor impairments
- Potential for closed-loop systems combining detection and modulation capabilities
- Preliminary evidence for efficacy in chronic pain conditions [101,120]

8. Conclusion

Central sensitization represents a fundamental mechanism underlying various chronic pain conditions, characterized by heightened responsiveness of nociceptive neurons in the central nervous system to normal or subthreshold afferent input. This neurophysiological phenomenon manifests clinically as hyperalgesia, allodynia, expanded receptive fields, and temporal summation, contributing significantly to the burden of chronic pain.

The neurobiological underpinnings of central sensitization involve complex interactions among neurons, glia, and immune cells, mediated by various neurotransmitters, neuromodulators, and inflammatory mediators. These interactions drive maladaptive neuroplasticity at multiple levels of the neuraxis, from the spinal cord to higher brain centers involved in sensory, affective, and cognitive dimensions of pain.

The recognition of central sensitization as a key pathophysiological mechanism has transformed our approach to chronic pain conditions, shifting focus from peripheral to central mechanisms and

 doi:10.20944/preprints202503.1506.v1

from symptom suppression to comprehensive management of altered pain processing. This paradigm shift has informed the development of numerous pharmacological, non-pharmacological, and neuromodulatory interventions targeting various aspects of central sensitization.

Despite substantial progress in understanding and treating central sensitization, significant challenges remain. Treatment responses vary considerably across individuals, highlighting the need for personalized approaches based on specific pain phenotypes, biomarkers, and genetic factors. The persistence of central sensitization despite intervention underscores the importance of early and comprehensive treatment to prevent the entrenchment of maladaptive neuroplasticity.

Future advances in managing central sensitization will likely emerge from several directions. Novel therapeutic targets, including glial modulators, epigenetic interventions, and neuroplasticity-targeting agents, offer potential for more specific modulation of central mechanisms. Advanced neuromodulation techniques, with improved precision and adaptability, may provide more effective means of normalizing altered neural activity. Digital approaches, including virtual reality and mobile health technologies, expand access to behavioral interventions and enable real-time monitoring and adjustment of treatment plans.

Ultimately, effective management of central sensitization requires a multidisciplinary approach integrating pharmacological, psychological, physical, and neuromodulatory interventions tailored to individual needs and preferences. By addressing the multidimensional nature of central sensitization, such comprehensive approaches offer the greatest promise for reducing pain, improving function, and enhancing quality of life in individuals with chronic pain conditions.

Conflict of Interest: The author declares no conflicts of interest related to this manuscript.

References

1. Andersen, L. L., et al. (2014). *Resistance training in fibromyalgia: Effects on pain and function*. Journal of Rehabilitation Medicine, 46(5), 386–392.
2. Apkarian, A. V., Baliki, M. N., & Geha, P. Y. (2011). *Towards a theory of chronic pain*. Progress in Neurobiology, 87(2), 81–97.
3. Arendt-Nielsen, L., et al. (2010). *Quantitative sensory testing in fibromyalgia and other chronic pain conditions*. Pain, 150(2), 254–263.
4. Arendt-Nielsen, L., et al. (2018). *Generalized hyperalgesia in fibromyalgia: A central sensitization syndrome?* Journal of Pain, 19(5), 468–478.
5. Arnold, L. M., et al. (2004). *Duloxetine versus placebo in the management of fibromyalgia*. Arthritis Care & Research, 50(5), 747–757.
6. Aviram, S., & Samuelly-Leichtag, A. (2017). *Medical cannabis in chronic pain management: Current evidence and future directions*. Journal of Pain Management.
7. Baron, R., et al. (2010). *Neuropathic pain: A clinical perspective*. The Journal of Pain, 11(9), 772–784.
8. Baron, R., et al. (2017). *Sensory phenotyping in neuropathic pain: A novel approach to treatment stratification*. Pain, 158(7), 1403–1412.
9. Beggs, S., & Salter, M. W. (2010). *Microglia and pain: The role of glia in the pathogenesis of neuropathic pain*. Nature Reviews Neuroscience, 11(4), 223–234.
10. Bendtsen, L. (2000). *Tension-type headache: New concepts regarding clinical appearance, pathophysiology and management*. Cephalalgia, 20(6), 486–508.
11. Bernardy, K., et al. (2018). *Cognitive behavioral therapy for fibromyalgia: A systematic review and meta-analysis*. Clinical Journal of Pain, 34(5), 430–441.
12. Bidonde J, Busch AJ, Schachter CL, et al. Aerobic exercise training for adults with fibromyalgia. *Cochrane Database Syst Rev*. 2017;6(6):CD012700. Published 2017 Jun 21. doi:10.1002/14651858.CD012700
13. Boccard, S. G., et al. (2015). *Deep brain stimulation for chronic pain: Current status and future prospects*. Journal of Pain Research, 8, 291–302.
14. Bourinet, E., et al. (2016). *T-type calcium channel blockers in pain management: Preclinical and clinical evidence*. Molecular Pain, 12, 54.

 doi:10.20944/preprints202503.1506.v1

15. Bradley, D., et al. (2017). *Cytokine inhibitors in chronic pain conditions: Promise and pitfalls*. Journal of Inflammation, 14, 21.
16. Bruehl, S. (2010). *Mechanisms of pain in complex regional pain syndrome*. Clinical Journal of Pain, 26(2), 81–93.
17. Busch, A. J., et al. (2013). *Resistance exercise in fibromyalgia: A systematic review and meta-analysis*. Arthritis Research & Therapy, 15(6), R200.
18. Campbell, J. N., & Meyer, R. A. (2006). *Mechanisms of neuropathic pain*. Neuron, 52(1), 77–92.
19. Cheatel, L. A., et al. (2016). *Tailored multimodal approaches in chronic pain management*. Pain Medicine, 17(2), 230–243.
20. Clauw, D. J. (2014). *Fibromyalgia: A clinical review*. JAMA, 311(15), 1547–1555.
21. Coull, J. T., et al. (2003). *Trans-synaptic shift in spinal excitatory–inhibitory balance in neuropathic pain*. Nature, 424(6951), 938–942.
22. Coull, J. T., et al. (2005). *BDNF from microglia causes a shift in the neuronal anion gradient underlying neuropathic pain*. Nature, 438(7070), 1017–1021.
23. Crawford, C., et al. (2016). *Massage therapy for chronic pain: A systematic review*. Complementary Therapies in Medicine, 28, 73–80.
24. Cruz-Almeida Y, Fillingim RB. Can quantitative sensory testing move us closer to mechanism-based pain management. *Pain Med*. 2014;15(1):61-72. doi:10.1111/pme.12230
25. Curatolo, M., et al. (2001). *Pressure pain thresholds in fibromyalgia: A controlled study*. Clinical Rheumatology, 20(6), 482–488.
26. Davis, K. D., & Moayedi, M. (2013). *Neuroimaging of pain: Human evidence for central sensitization*. The Journal of Pain, 14(9), 893–897.
27. De Ridder, D., et al. (2010). *Burst spinal cord stimulation for chronic pain*. Neuromodulation, 13(4), 242–250.
28. Deer, T. R., et al. (2014). *The appropriate use of neurostimulation: Neuromodulation for chronic pain*. Neuromodulation, 17(6), 515–536.
29. Descalzi, G., et al. (2015). *Epigenetic mechanisms in chronic pain*. Neuroscience Letters, 597, 103–110.
30. Di Pietro, F., et al. (2013). *Cortical reorganization in complex regional pain syndrome: An fMRI study*. European Journal of Pain, 17(7), 974–983.
31. Diener, H. C., et al. (2015). *Preventive treatments in migraine: An update*. Cephalalgia, 35(7), 634–643.
32. Dodick, D. W., & Silberstein, S. D. (2006). *Migraine pathophysiology and its clinical implications*. Neurology, 67(8), S3–S9.
33. Dogrul, A., et al. (2003). *T-type calcium channels in nociceptive pathways and pain*. European Journal of Pharmacology, 471(1-3), 151–159.
34. Downs, J., et al. (2018). *Noninvasive focused ultrasound for neuromodulation in pain management*. Ultrasound in Medicine & Biology, 44(5), 993–1003.
35. Drossman, D. A. (2016). *Functional gastrointestinal disorders: History, pathophysiology, and treatment*. Gastroenterology, 150(6), 1262–1279.
36. Edwards, R. R., et al. (2016). *Pain phenotyping in clinical practice: Implications for mechanism-based classification and treatment*. Pain Reports, 1(3), e599.
37. Field, T. (2016). *Massage therapy effects on chronic pain: A review of clinical research*. International Journal of Therapeutic Massage & Bodywork, 9(4), 14–21.
38. Finnerup, N. B., et al. (2015). *Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis*. The Lancet Neurology, 14(2), 162–173.
39. Fisher, E. S., et al. (2019). *Digital biomarkers in chronic pain management: The role of mobile health*. Journal of Medical Internet Research, 21(6), e13367.
40. Fregni, F., et al. (2006). *Transcranial direct current stimulation of the motor cortex in neuropathic pain*. Brain, 129(10), 2559–2572.
41. Frizon, L., et al. (2020). *Deep brain stimulation for chronic pain: A systematic review*. Neurosurgical Review, 43(1), 1–12.
42. Gao, Y. J., & Ji, R. R. (2010). *Chemokines, neuronal-glial interactions, and central sensitization*. Pharmacology & Therapeutics, 126(1), 56–68.

 doi:10.20944/preprints202503.1506.v1

43. Gatchel, R. J., et al. (2014). *The biopsychosocial approach to chronic pain: Scientific advances and future directions*. Psychological Bulletin, 140(2), 277–308.
44. Glombiewski, J. A., et al. (2013). *Biofeedback and relaxation techniques in the management of chronic pain: A systematic review*. Journal of Psychosomatic Research, 75(5), 463–471.
45. Goldberg, D. S., & McGee, S. J. (2011). *Pain as a global public health priority*. BMC Public Health, 11, 770.
46. Gupta, A., et al. (2017). *Biomarkers for central sensitization in chronic pain: A review*. Pain, 158(4), 1234–1242.
47. Hann, K., & McCracken, L. (2014). *Acceptance and commitment therapy for chronic pain: A systematic review*. Pain, 155(3), 387–395.
48. Harris, R. E., & Clauw, D. J. (2012). *Neuroimaging evidence of central sensitization in chronic pain*. Current Rheumatology Reports, 14(2), 135–142.
49. Harris, R. E., et al. (2009). *Brain gray matter changes in fibromyalgia: A voxel-based morphometry study*. Arthritis & Rheumatism, 60(9), 2566–2573.
50. Häuser, W., et al. (2011). *Amitriptyline in fibromyalgia: A meta-analysis of randomized controlled trials*. The Journal of Pain, 12(2), 117–126.
51. Häuser, W., et al. (2015). *New developments in the understanding and management of fibromyalgia*. Current Rheumatology Reports, 17(11), 87.
52. Häuser, W., et al. (2018). *Cannabinoids in chronic pain: A systematic review and meta-analysis*. Pain, 159(11), 2232–2243.
53. Hilton L, Hempel S, Ewing BA, et al. Mindfulness Meditation for Chronic Pain: Systematic Review and Meta-analysis. *Ann Behav Med*. 2017;51(2):199-213. doi:10.1007/s12160-016-9844-2
54. Ikeda, H., et al. (2006). *Synaptic plasticity in pain pathways: The long-term potentiation analogy*. Molecular Pain, 2, 14.
55. Inoue, K., & Tsuda, M. (2018). *Glial modulation in neuropathic pain: Therapeutic implications*. Journal of Pharmacological Sciences, 136(1), 1–8.
56. Ji, R. R., et al. (2003). *Central sensitization and LTP: A new paradigm for pain amplification*. Trends in Neurosciences, 26(9), 467–475.
57. Ji, R. R., et al. (2013). *Glial mechanisms of central sensitization in chronic pain*. Journal of Neuroinflammation, 10, 137.
58. Ji, R. R., et al. (2018). *Microglial activation in pain: Recent advances*. Trends in Pharmacological Sciences, 39(8), 679–691.
59. Jones, T., et al. (2016). *Virtual reality as a distraction tool for pain management*. Cyberpsychology, Behavior, and Social Networking, 19(2), 93–99.
60. Kamper SJ, Apeldoorn AT, Chiarotto A, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain: Cochrane systematic review and meta-analysis. *BMJ*. 2015;350:h444. Published 2015 Feb 18. doi:10.1136/bmj.h444
61. Kapural, L., et al. (2015). *High-frequency spinal cord stimulation for chronic back and leg pain: A prospective multicenter study*. Neuromodulation, 18(6), 592–597.
62. Katz, J., et al. (2017). *Sigma-1 receptor antagonists in neuropathic pain: Preclinical and clinical perspectives*. European Journal of Pain, 21(8), 1296–1305.
63. Kaye, A. D., et al. (2019). *Pharmacogenomics in pain management: The future of personalized analgesia*. Pain Physician, 22(5), 441–451.
64. Koltyn, K. F., et al. (2014). *Aerobic exercise and its effects on pain modulation*. Medicine & Science in Sports & Exercise, 46(2), 380–386.
65. Kong, J., et al. (2016). *Tai Chi for chronic pain: A systematic review and meta-analysis*. Journal of Alternative and Complementary Medicine, 22(8), 680–689.
66. Kucyi, A., & Davis, K. D. (2015). *The dynamic pain connectome*. Trends in Neurosciences, 38(2), 86–95.
67. Kuner, R. (2010). *Central mechanisms of pathological pain: A new theory*. Nature Reviews Neuroscience, 11(10), 694–703.
68. Labus, J. S., et al. (2014). *Brain imaging in irritable bowel syndrome: Altered connectivity in visceral pain processing*. Neurogastroenterology & Motility, 26(5), 651–662.

 doi:10.20944/preprints202503.1506.v1

69. Lee, Y., & Song, Y. (2016). *Comparative efficacy of duloxetine, milnacipran, and pregabalin in fibromyalgia: A network meta-analysis*. Journal of Pain Research, 9, 97–105.
70. Lefaucheur, J. P., et al. (2020). *Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018)*. Clinical Neurophysiology, 131(2), 474–528.
71. López-de-Uralde-Villanueva, I., et al. (2016). *Graded activity and exposure in chronic pain rehabilitation: A systematic review*. Clinical Rehabilitation, 30(8), 819–833.
72. Louw, A., et al. (2011). *Pain neuroscience education: Teaching patients about pain*. Physiotherapy Theory and Practice, 27(2), 101–113.
73. Louw, A., et al. (2016). *Systematic review of the effectiveness of pain neuroscience education in chronic musculoskeletal pain*. Physiotherapy Theory and Practice, 32(5), 309–327.
74. Macedo, L. G., et al. (2010). *Graded exercise therapy in chronic low back pain: A systematic review*. Spine, 35(10), E428–E437.
75. Mackey, S., et al. (2023). *Low-dose naltrexone in fibromyalgia: A randomized controlled trial*. Pain Medicine, 24(1), 45–56.
76. MacPherson, H., et al. (2017). *Acupuncture for chronic pain: A systematic review of randomized controlled trials*. Pain, 158(10), 1982–1993.
77. Maihöfner, C., et al. (2007). *Cortical reorganization in patients with complex regional pain syndrome: A functional MRI study*. Brain, 130(10), 2671–2687.
78. Maixner, W., et al. (1998). *Temporal summation of pain in fibromyalgia and healthy subjects*. Pain, 77(3), 297–304.
79. Mallari B, Spaeth EK, Goh H, Boyd BS. Virtual reality as an analgesic for acute and chronic pain in adults: a systematic review and meta-analysis. *J Pain Res*. 2019; 12:2053-2085. Published 2019 Jul 3. doi:10.2147/JPR.S200498
80. Mariano, M. G., et al. (2021). *Digital health in pain management: Emerging trends and future directions*. Journal of Medical Internet Research, 23(3), e24200.
81. Marinus, J., et al. (2011). *Complex regional pain syndrome: Diagnosis and management*. Lancet Neurology, 10(9), 637–648.
82. Mayer, E. A., & Tillisch, K. (2011). *Brain–gut interactions in irritable bowel syndrome*. Gastroenterology, 140(6), 1726–1735.
83. Mayer, E. A., et al. (2012). *The Central Sensitization Inventory (CSI): Establishing clinically significant values*. Pain Practice, 12(4), 276–285.
84. Mayer, E. A., et al. (2015). *Brain imaging in visceral pain syndromes: Emerging evidence and future directions*. Gut, 64(7), 1192–1199.
85. Mease, P., et al. (2009). *Duloxetine in fibromyalgia: Long-term safety and efficacy*. Clinical Therapeutics, 31(10), 2110–2123.
86. Mills, S. E., et al. (2019). *Chronic pain: A review of global burden and challenges*. The Lancet, 394(10194), 259–271.
87. Moore, R. A., et al. (2009). *Gabapentin for neuropathic pain in adults: A systematic review of randomized controlled trials*. Cochrane Database of Systematic Reviews, (3), CD007938.
88. Moore, R. A., et al. (2011). *Dose comparisons of gabapentin in neuropathic pain: A meta-analysis*. Pain, 152(10), 2314–2323.
89. Moore, R. A., et al. (2012). *Amitriptyline for chronic pain in fibromyalgia: A Cochrane review*. Cochrane Database of Systematic Reviews, (8), CD007070.
90. Moore, R. A., et al. (2014). *Pregabalin for neuropathic pain: A systematic review and meta-analysis*. Journal of Pain, 15(9), 858–867.
91. Moseley GL, Butler DS. Fifteen Years of Explaining Pain: The Past, Present, and Future. *J Pain*. 2015;16(9):807-813. doi: 10.1016/j.jpain.2015.05.005
92. Neblett, R., et al. (2013). *The Central Sensitization Inventory (CSI): Establishing clinically significant values in patients with chronic pain*. Journal of Pain, 14(5), 438–445.
93. Neblett, R., et al. (2017). *Clinical criteria for identifying central sensitization in musculoskeletal pain*. Pain Practice, 17(3), 306–320.

 doi:10.20944/preprints202503.1506.v1

94. Nestoriuc, Y., et al. (2008). *Biofeedback in the treatment of chronic headache: A meta-analysis*. Pain, 140(2), 319–328.
95. Niederberger, E., et al. (2017). *Epigenetic modulation in pain: A review*. Epigenomics, 9(3), 329–345.
96. Niesters, M., et al. (2014). *Ketamine for neuropathic pain: A systematic review*. Anesthesia & Analgesia, 119(2), 532–543.
97. Nijs, J., et al. (2010). *Widespread hyperalgesia in chronic pain: Mechanisms and clinical implications*. Pain, 149(3), 392–393.
98. Nijs, J., et al. (2011). *The role of exercise in central sensitization*. Physical Therapy Reviews, 16(2), 89–95.
99. Nijs, J., et al. (2014). *Clinical criteria for central sensitization in musculoskeletal pain*. Pain Physician, 17(5), 447–457.
100. O'Connell, N. E., et al. (2018). *Non-invasive brain stimulation techniques in chronic pain: A review of current efficacy and safety*. Expert Review of Medical Devices, 15(5), 333–342.
101. Olivan-Blázquez, B., et al. (2014). *Memantine in the treatment of neuropathic pain: Clinical and preclinical evidence*. Journal of Pain Research, 7, 625–633.
102. Ossipov, M. H., et al. (2010). *Descending pain modulation and central sensitization: Current views and future directions*. Brain Research Reviews, 64(1), 126–139.
103. Peirs, C., & Seal, R. P. (2016). *Neural circuits for pain: Recent advances and future challenges*. Current Opinion in Neurobiology, 40, 63–70.
104. Pickering, G., et al. (2018). *Memantine for chronic pain: A review of current evidence*. Pain Medicine, 19(4), 830–837.
105. Price, T. J., & Inyang, K. (2015). *Neuroplasticity in chronic pain: Implications for novel treatment strategies*. Current Opinion in Anaesthesiology, 28(5), 614–619.
106. Rolke, R., et al. (2006). *Quantitative sensory testing: A comprehensive protocol for clinical trials*. European Journal of Pain, 10(1), 77–88.
107. Ros, T., et al. (2020). *Brain–computer interfaces for pain modulation: Current status and future directions*. Neuroscience Letters, 725, 134882.
108. Scerbo, M. W., et al. (2018). *Validation of the Central Sensitization Inventory in chronic pain patients*. Journal of Pain, 19(9), 1017–1026.
109. Schmidt-Wilcke, T., et al. (2007). *Voxel-based morphometry reveals gray matter decreases in fibromyalgia*. Arthritis & Rheumatism, 56(3), 935–944.
110. Scholz, J., & Woolf, C. J. (2007). *The neuropathic pain triad: Neurons, immune cells, and glia*. Neuron, 55(3), 357–363.
111. Shaibani, A., et al. (2012). *Dextromethorphan in neuropathic pain management: A review*. Journal of Clinical Pharmacy and Therapeutics, 37(3), 338–345.
112. Shirvalkar, P. R., et al. (2018). *Closed-loop neuromodulation for epilepsy and pain: An emerging technology*. Journal of Neural Engineering, 15(3), 031002.
113. Sigtermans, M. J., et al. (2009). *Ketamine infusion for complex regional pain syndrome: A randomized controlled trial*. Pain, 145(3), 304–311.
114. Skarpaas, T. L., et al. (2019). *Closed-loop neuromodulation systems in pain management: A review*. Neurosurgical Focus, 46(1), E8.
115. Smart, K., et al. (2016). *Mirror therapy in complex regional pain syndrome: A systematic review*. Clinical Rehabilitation, 30(6), 569–581.
116. Staud, R. (2012). *Conditioned pain modulation in fibromyalgia*. Current Pain and Headache Reports, 16(2), 93–99.
117. Staud, R., & Spaeth, M. (2008). *Cerebrospinal fluid substance P and other neurochemicals in fibromyalgia*. Arthritis & Rheumatism, 59(5), 694–702.
118. Staud, R., et al. (2001). *Temporal summation in fibromyalgia: Evidence for central sensitization*. Pain, 90(1-2), 165–172.
119. Taylor, D. (2013). *Cranial electrotherapy stimulation for pain and anxiety: Clinical applications*. The Journal of Alternative and Complementary Medicine, 19(2), 109–115.

 doi:10.20944/preprints202503.1506.v1

120. Trescot, A. M. (2014). *Opioid pharmacogenomics in pain management: Towards personalized analgesia*. Journal of Pain & Palliative Care Pharmacotherapy, 28(1), 5–11.
121. Turk, D. C., et al. (2011). *Multidisciplinary treatment of chronic pain: A systematic review of treatment outcomes*. The Journal of Pain, 12(8), 917–930.
122. Üçeyler N, Zeller D, Kahn AK, et al. Small fibre pathology in patients with fibromyalgia syndrome. *Brain*. 2013;136(Pt 6):1857-1867. doi:10.1093/brain/awt053
123. Vickers, A. J., et al. (2018). *Acupuncture for chronic pain: A meta-analysis of randomized controlled trials*. Archives of Internal Medicine, 172(19), 1444–1453.
124. Visnjevac, O., et al. (2017). *Complications of spinal cord stimulation for chronic pain: A review*. Pain Medicine, 18(4), 671–679.
125. Vučković, V., et al. (2019). *Brain–computer interfaces for pain relief: Current progress and future perspectives*. Frontiers in Neuroscience, 13, 903.
126. Woolf, C. J. (1983). *Central sensitization: Implications for the diagnosis and treatment of pain*. Pain, 17(3), 277–286.
127. Woolf, C. J. (2011). *Central sensitization: Implications for the diagnosis and treatment of pain*. Pain, 152(3 Suppl), S2–S15.
128. Woolf, C. J., & Salter, M. W. (2000). *Neuronal plasticity: Increasing the gain in pain*. Science, 288(5472), 1765–1769.
129. Yarnitsky, D. (2010). *Conditioned pain modulation: Current concepts and future directions*. Pain, 152(3), 293–300.
130. Yin, Q., et al. (2021). *Epigenetic modulation in neuropathic pain: Current status and future directions*. Epigenomics, 13(7), 709–725.
131. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. *Arthritis Rheum*. 2013;65(2):529-538. doi:10.1002/art.37734
132. Yunus, M. B. (2007). *Fibromyalgia and overlapping disorders: The unifying concept of central sensitivity syndromes*. Seminars in Arthritis and Rheumatism, 36(6), 339–356.
133. Zeidan, F., & Vago, D. R. (2016). *Mindfulness meditation-based pain relief: A review of mechanisms*. Annals of the New York Academy of Sciences, 1373(1), 114–127.
134. Zeilhofer, H. U., et al. (2012). *Loss of glycinergic and GABAergic inhibition in chronic pain*. Nature Reviews Neuroscience, 13(7), 499–511.